Conference abstract · 7 Nov 2016
Conference abstractPublished 3 Oct 2016
From discovering “calcium paradox” to Ca2+/cAMP interaction: impact in human health and disease
UNIFESP-Escola Paulista de Medicina (EPM), Brazil
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The hypothesis of the so-called “calcium paradox” phenomenon in the sympathetic neurotransmission has its origin in experiments done in models of neurotransmission since 1970´s. Historically, “calcium paradox” originated several clinical studies reporting that acute and chronic administration of L-type Ca2+ Channel Blockers (CCBs), drugs largely used for antihypertensive therapy such as verapamil and nifedipine, produces reduction in peripheral vascular resistance and arterial pressure, associated with a paradoxical sympathetic hyperactivity. Despite this sympathetic hyperactivity has been initially attributed to adjust reflex of arterial pressure, the cellular and molecular mechanisms involved in this paradoxical effect of the L-type CCBs remained unclear for four decades. Also, experimental studies using isolated tissues richly innervated by sympathetic nerves showed that neurogenic responses were completely inhibited by L-type CCBs in high concentrations, but paradoxically potentiated in low concentrations, characterized as a “calcium paradox” phenomenon. We discovered in 2013 that this paradoxical increase in sympathetic activity produced by L-type CCBs is due to Ca2+/cAMP interaction (Bergantin et al., Cell Calcium, 2013; ScienceDirect TOP 25 Hottest Articles - Cell Calcium - TOP 1 July to September 2013/ TOP 5 October to December 2013/ TOP 1 January to December 2013 full year/TOP 6 January to March 2014). Then, the pharmacological manipulation of this interaction could represent a potential cardiovascular risk for hypertensive patients due to increase of sympathetic hyperactivity. In contrast, this pharmacological manipulation could be a new therapeutic strategy for increasing neurotransmission in psychiatric disorders such as depression, and producing neuroprotection in the neurodegenerative diseases such as Alzheimer´s and Parkinson´s diseases (Caricati-Neto et al. 2015, Pharmacol Res Perspectives; Bergantin and Caricati-Neto 2016, Eur J Pharmacol).
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Review article · 30 Jun 2020
The Calcium Paradox due to Ca2+/cAMP Interaction and Antihypertensive Pharmacotherapy: New Avenues for Drug Development
Editorial · 2018
Revisiting the Clinical Link Between Alzheimer's Disease and Depression Through the Ca2+/Camp Signalling Interaction
Review article · 26 Sep 2017
Huntington´s disease and the interaction between Ca2+ and cAMP signaling pathways
Short communication · 2017
Sudden Unexpected Death in Parkinsonâ??s Disease and the Pharmacological Modulation of the Ca2+/cAMP Signaling Interaction: A Shot of Good News
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- BylineArticles whose byline prints “Leandro Bueno Bergantin”
